Gene Therapy Shows Remarkable Results for Sickle Cell Anemia Patient
A 20-year-old man in St. Louis, Missouri, received gene therapy called Lyfgenia for sickle cell anemia and experienced significant positive results, with his body reportedly becoming nearly free of sickle cells after 20 years of living with the disease. The…
Greenville Spartanburg Asheville Anderson, SC, August 10, 2026 —
A significant advancement in the treatment of sickle cell anemia is demonstrating remarkable outcomes, as evidenced by the case of a 20-year-old man in St. Louis, Missouri.
The individual underwent treatment with Lyfgenia, a gene therapy approved by the U.S. Food and Drug Administration (FDA) in late 2023. Following the therapy, his body has reportedly become nearly free of sickle cells, a stark contrast to his previous 20 years of living with the debilitating disease.
Sickle cell anemia is a genetic disorder characterized by abnormal hemoglobin, leading to the misshapen “sickle” form of red blood cells. These cells can block blood flow, causing pain, organ damage, and other serious complications.
Lyfgenia operates by utilizing a patient’s own stem cells, which are then treated to correct the underlying genetic defect responsible for sickle cell disease. This approach is part of a growing wave of personalized and advanced therapies targeting inherited conditions.
The promising results observed in this case highlight the potential of gene therapy to offer transformative solutions for patients with previously intractable genetic disorders. While the therapy is showing encouraging outcomes, it is noted that it is suitable for those who qualify for the treatment.
The FDA approval in late 2023 marked a critical step in making such innovative treatments available to patients. Further details regarding the specific protocol or long-term monitoring of this patient were not provided.
Story summarized from the original created by LeAnne Gendreau on www.foxcarolina.com, see more information here.